Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38

We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.

The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.

Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.

--------------------

This episode is sponsored by Kadans. Learn more about Kadans’ London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio

--------------------

⭐️ ABOUT THE SPEAKER

Robin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection.

🔗 LINKS MENTIONED

• - Myricx Bio’s website: (https://tiltbio.com/)https://myricxbio.com/
• - Myrcix Bio’s Series A round: (https://tiltbio.com/userassets/uploads/2025/05/TILT-Series-B-press-release-May-2025.pdf)https://myricxbio.com/myricx-bio-announces-90m-114m-series-a-financing-to-advance-its-novel-nmti-adc-therapeutics-into-clinical-development/
• - A winding road – the many adventures of a promising ADC - Cancer Research UK: https://news.cancerresearchuk.org/2024/07/09/a-winding-road-the-many-adventures-of-a-promising-adc/
• - Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/

📜 TRANSCRIPT

Read the full transcript here: https://flot.bio/episode/robin-carr-myricx-bio-adc/

💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP

Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US

• - Newsletter: http://eepurl.com/h_fnmH
• - LinkedIn: https://www.linkedin.com/company/flot-bio/
• - X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW

Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO

Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.

⏰ TIMESTAMPS

• [00:00:00] Intro
• [00:02:43] Navigating biotech networking
• [00:07:30] Myricx’s Series A and transformation
• [00:10:45] The pivot to ADCs
• [00:22:10] NMT ADCs in cancer
• [00:32:09] The big pharma to biotech leap
• [00:42:39] ADCs in Europe, the US and Asia
• [00:46:17] ADCs are a booming market
• [00:52:35] Quick-fire questions